Compare Eli Lilly And Co (LLY) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Rocket Lab USA Inc — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Rocket Lab USA Inc trades at $68.22 (market cap $43.74B). The key difference: Eli Lilly And Co is far larger — about 23.8× Rocket Lab USA Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Rocket Lab USA Inc for 29 Days on average.
| LLY | RKLB | |
|---|---|---|
Market Cap | $1.04T | $43.74B |
Volume | 3,064,878 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $1.28K | $150.23 |
52-Week Low | $799.57 | $39.48 |
Typical Hold Time | 93 Days | 29 Days |
Enterprise Value | $1.09T | $41.57B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Rocket Lab (RKLB) trades at $68.35, down 4.96% in the last session, reflecting a bearish technical trend. The company's fundamentals show strong revenue growth, with 2026 revenue projected at $769 million, but it remains unprofitable with a net loss of -$165 million. Recent positive news includes securing its largest-ever commercial Electron launch deal with Synspective, boosting its backlog to over 100 missions. Analyst sentiment is predominantly bullish, with a consensus price target of $107.00.
The outlook for RKLB hinges on execution of its growing launch backlog and path to profitability. Investment opportunity lies in its leading position in small satellite launch services and expanding spacecraft business. Key risks include intense competition from SpaceX, high cash burn, and reliance on future Neutron rocket success. The stock offers high growth potential but carries significant execution and valuation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
